Cyfra 21-1 is a sensitive and specific tumor marker of non-small cell lung carcinoma (NSCLC), especially of the squamous cell subtype. It also reflects the extent of the disease and has an independent prognostic role along with performance status and disease stage in NSCLC. Elevated levels of Cyfra 21-1 can be used to monitor disease progression and response to therapy.